Lycia Therapeutics
LYCA on NasdaqBiological products (no diagnostic substances)
Dilution Known so far: 17.6M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM. Every source
Lycia Therapeutics’ latest filing is a Form 4 from . Every Lycia Therapeutics filing is below, newest first.
Insiders 1 insider bought $38.3M of Lycia Therapeutics stock on the open market in the last 90 days. Every trade
Venrock Healthcare Capital Partners III, L.P. (10% owner) bought 25,004 LYCA at $25.78, worth $645K
- Purchased 10,570 shares at $25.23
- Purchased 4,430 shares at $25.97
- Purchased 8,804 shares at $26.27
IPO registration
Priced and listed · S-1/A filed Oct 20, 2026
- Registration declared effective EFFECT
- Amended registration S-1/A
- Shares registered for exchange listing 8-A12B
- Registration filed S-1
- Amended draft registration DRS/A
- Draft registration, filed confidentially DRSFirst filing
All filings
Latest: the 2 newest filings, key filings first. Each other tab counts its kind among the 36 most recent EDGAR filings.
Results, 8-Ks and Major or Notable filings come first, then registrations and share actions, then everything else, newest first. Routine filings are kept here unmarked; insider filings are summed up in one line.
1 insider bought $38.3M of Lycia Therapeutics stock on the open market in the last 90 days. Every LYCA insider trade
Offerings and dilution 6
| Date | Form | What it is |
|---|---|---|
| Oct 23, 2026 | S-8 | Employee stock plan registration |
| Oct 23, 2026 | 424B4 | Prospectus |
| Oct 22, 2026 | EFFECT | Registration declared effective |
| Oct 22, 2026 | S-1MEF | S-1MEF |
| Oct 20, 2026 | S-1/A | Registration for a share sale (amended) Key exhibits: Underwriting or sales agreement (EX-1.1), Warrants or notes (EX-4.1), Material contract (EX-10.3), Material contract (EX-10.4), Material contract (EX-10.5), Material contract (EX-10.7) |
| Oct 5, 2026 | S-1 | Registration for a share sale Key exhibits: Warrants or notes (EX-4.2), Material contract (EX-10.1), Material contract (EX-10.2), Material contract (EX-10.6), Material contract (EX-10.8), Material contract (EX-10.9) |
Insiders 21
| Date | Form | What it is |
|---|---|---|
| Oct 30, 2026 | Form 4 | Venrock Healthcare Capital Partners III, L.P. (10% owner) bought 25,004 LYCA at $25.78, worth $645K |
| Oct 26, 2026 | Form 4 | Sofia Touami (Chief Business Officer) reported option or other derivative trades in LYCA |
| Oct 26, 2026 | Form 4 | Steven Staben (Chief Scientific Officer) reported option or other derivative trades in LYCA |
| Oct 26, 2026 | Form 4 | Amy Bachrodt (CFO) reported option or other derivative trades in LYCA |
| Oct 26, 2026 | Form 4 | Chin Hyok Lee (Chief Medical Officer) reported option or other derivative trades in LYCA |
| Oct 26, 2026 | Form 4 | Aetna Wun Trombley (CEO) reported option or other derivative trades in LYCA |
| Oct 26, 2026 | Form 4 | Jane Henderson (Director) reported option or other derivative trades in LYCA |
| Oct 26, 2026 | Form 4 | Laurent Fischer (Director) reported option or other derivative trades in LYCA |
13 older insiders filings on EDGAR.
Governance 1
| Date | Form | What it is |
|---|---|---|
| Oct 26, 2026 | 8-K | Amends its charter or bylaws |
Other 8
Possible new shares
Known so far: 17.6M possible new shares · no effective shelf · not yet read: warrants, converts, options, ATM.
- 17.6M new shares from the 424B4 of Oct 23, 2026
Not read yet: warrants, convertible notes, options and RSUs and an ATM program.
Listing compliance
No listing notices in the 8-K item 3.01 filings SEC Tracker has read.
Dates and rules are as stated in each 8-K item 3.01 filing; a blank means the filing did not state one. Read the filing for the full terms. All open notices
Trading halts
No trading halts for LYCA since Feb 22, 2019, when SEC Tracker began reading the Nasdaq Trader feed.
Halt times and codes from the Nasdaq Trader trade halts feed, which lists Nasdaq and other exchange halts. Filings matched by SEC Tracker from EDGAR by company and time. Not investment advice. All recent halts
Insiders
Show the 5 latest Form 4 trades
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. The Stake column is the change in their holding.
| Traded | Insider | Trade | Value | Stake | Notes |
|---|---|---|---|---|---|
| Oct 30, 2026 | Venrock Healthcare Capital Partners III 10% owner | Open-market buy 9,004 shares in 2 lines | $237K at $26.28 | The same day as the company's SCHEDULE 13G filed Oct 30, 2026. | |
| Oct 29, 2026 Filed Oct 30, 2026 | Venrock Healthcare Capital Partners III 10% owner | Open-market buy 1,000 shares | $26K at $26.33 | +<1% | 3 days after the company's 8-K filed Oct 26, 2026. |
| Oct 28, 2026 Filed Oct 30, 2026 | Venrock Healthcare Capital Partners III 10% owner | Open-market buy 15,000 shares in 2 lines | $382K at $25.45 | 2 days after the company's 8-K filed Oct 26, 2026. | |
| Oct 27, 2026 | Venrock Healthcare Capital Partners III 10% owner | Open-market buy 39,796 shares in 2 lines | $1.1M at $26.62 | 1 day after the company's 8-K filed Oct 26, 2026. | |
| Oct 26, 2026 Filed Oct 27, 2026 | Venrock Healthcare Capital Partners III 10% owner | Open-market buy 1,944,444 shares | $35M at $18.00 | +40% | The same day as the company's 8-K filed Oct 26, 2026. |
Open-market buys and sales (Form 4 codes P and S); planned sales are marked under a Rule 10b5-1 plan. Values as stated in each Form 4. Not investment advice. Every Form 4 for LYCA · Insider trades across companies
Coming up
- Offering lock-up ends, about 90 days after the 424B4 of Oct 23 424B4, filed Oct 23
- Offering lock-up ends, about 180 days after the 424B4 of Oct 23 424B4, filed Oct 23
- Primary completion of the trial "Single Ascending and Multiple Ascending Dose Study of LCA-0061" ClinicalTrials.gov NCT07701954
Dates and exhibits are as stated in each filing on EDGAR; a date no filing states is not shown. Not investment advice.
Lycia Therapeutics shares and listing
From the company's own filings; each row names its source. Not investment advice.
- Listing compliance8-K item 3.01No noticesin the filings read
Insider activity
1 insider bought $38.3M of Lycia Therapeutics stock on the open market in the last 90 days.
Notable buy: 10% owner bought $237K
- 10% owner bought $237K
- 10% owner bought $26K
- 10% owner bought $382K
Stakes Lycia Therapeutics reports in other companies
Filings Lycia Therapeutics made as a holder or insider of another company. They are about that company, not Lycia Therapeutics.
- Venrock Healthcare Capital Partners III (LYCA) Schedule 13G
Similar companies
Same SIC code (2836 Biological products (no diagnostic substances)) and public float not reported.
- Adaptimmune Therapeutics ADAP
- Adverum Biotechnologies ADVM
- AgomAb Therapeutics AGMB
- Alvotech ALVO
- Argenx ARGX